273 related articles for article (PubMed ID: 31403344)
1. Concepts for agonistic targeting of CD40 in immuno-oncology.
Richards DM; Sefrin JP; Gieffers C; Hill O; Merz C
Hum Vaccin Immunother; 2020; 16(2):377-387. PubMed ID: 31403344
[TBL] [Abstract][Full Text] [Related]
2. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
3. The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy.
Frankish J; Mukherjee D; Romano E; Billian-Frey K; Schröder M; Heinonen K; Merz C; Redondo Müller M; Gieffers C; Hill O; Thiemann M; Honeychurch J; Illidge T; Sykora J
Front Immunol; 2023; 14():1160116. PubMed ID: 37304285
[TBL] [Abstract][Full Text] [Related]
4. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis.
Bugajska U; Georgopoulos NT; Southgate J; Johnson PW; Graber P; Gordon J; Selby PJ; Trejdosiewicz LK
J Natl Cancer Inst; 2002 Sep; 94(18):1381-95. PubMed ID: 12237284
[TBL] [Abstract][Full Text] [Related]
5. Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.
Karnell JL; Rieder SA; Ettinger R; Kolbeck R
Adv Drug Deliv Rev; 2019 Feb; 141():92-103. PubMed ID: 30552917
[TBL] [Abstract][Full Text] [Related]
6. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
[TBL] [Abstract][Full Text] [Related]
7. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.
Tang T; Cheng X; Truong B; Sun L; Yang X; Wang H
Pharmacol Ther; 2021 Mar; 219():107709. PubMed ID: 33091428
[TBL] [Abstract][Full Text] [Related]
9. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.
Danese S; Sans M; Scaldaferri F; Sgambato A; Rutella S; Cittadini A; Piqué JM; Panes J; Katz JA; Gasbarrini A; Fiocchi C
J Immunol; 2006 Feb; 176(4):2617-24. PubMed ID: 16456024
[TBL] [Abstract][Full Text] [Related]
10. Small multivalent architectures mimicking homotrimers of the TNF superfamily member CD40L: delineating the relationship between structure and effector function.
Trouche N; Wieckowski S; Sun W; Chaloin O; Hoebeke J; Fournel S; Guichard G
J Am Chem Soc; 2007 Nov; 129(44):13480-92. PubMed ID: 17935324
[TBL] [Abstract][Full Text] [Related]
11. Effect of CD40--CD40 ligand interaction on diacylglycerol-protein kinase C and inositol trisphosphate-Ca(2+) signal transduction pathway in human umbilical vein endothelial cells.
Yan JC; Wu ZG; Kong XT; Zong RQ; Zhan LZ
Clin Chim Acta; 2003 Nov; 337(1-2):133-40. PubMed ID: 14568189
[TBL] [Abstract][Full Text] [Related]
12. The CD40/CD40L system regulates rat cerebral microvasculature after focal ischemia/reperfusion via the mTOR/S6K signaling pathway.
Jiang RH; Xu XQ; Wu CJ; Lu SS; Zu QQ; Zhao LB; Liu S; Shi HB
Neurol Res; 2018 Sep; 40(9):717-723. PubMed ID: 29843579
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
14. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation.
Bachmann MF; Wong BR; Josien R; Steinman RM; Oxenius A; Choi Y
J Exp Med; 1999 Apr; 189(7):1025-31. PubMed ID: 10190893
[TBL] [Abstract][Full Text] [Related]
15. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand.
Wyzgol A; Müller N; Fick A; Munkel S; Grigoleit GU; Pfizenmaier K; Wajant H
J Immunol; 2009 Aug; 183(3):1851-61. PubMed ID: 19596991
[TBL] [Abstract][Full Text] [Related]
16. Integrin Binding to the Trimeric Interface of CD40L Plays a Critical Role in CD40/CD40L Signaling.
Takada YK; Yu J; Shimoda M; Takada Y
J Immunol; 2019 Sep; 203(5):1383-1391. PubMed ID: 31331973
[TBL] [Abstract][Full Text] [Related]
17. Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.
Gruss HJ; Duyster J; Herrmann F
Ann Oncol; 1996; 7 Suppl 4():19-26. PubMed ID: 8836404
[TBL] [Abstract][Full Text] [Related]
18. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues.
Gruss HJ; Herrmann F; Gattei V; Gloghini A; Pinto A; Carbone A
Leuk Lymphoma; 1997 Feb; 24(5-6):393-422. PubMed ID: 9086433
[TBL] [Abstract][Full Text] [Related]
19. In this issue: harnessing immunity against difficult targets, through the CD40-CD40L pathway.
Kornbluth RS; Bot A
Int Rev Immunol; 2012 Aug; 31(4):243-5. PubMed ID: 22804569
[TBL] [Abstract][Full Text] [Related]
20. A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity.
Thiemann M; Richards DM; Heinonen K; Kluge M; Marschall V; Merz C; Redondo Müller M; Schnyder T; Sefrin JP; Sykora J; Fricke H; Gieffers C; Hill O
Front Oncol; 2018; 8():387. PubMed ID: 30298117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
